US4992418A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Superactive human insulin analogue-[10-Aspartic Acid-B]Human Insulin
Assignee: Icahn School of Medicine at Mount Sinai
•
Filing: 1987-07-17
•
Granted: 1991-02-12
•
Expires: 2007-07-17
Abstract
Abstract A superactive insulin analogue of the formula ##STR1## is provided. This analogue is used in therapeutically effective amounts in the preparation of pharmaceutical compositions for administration to diabetic patients.
Inventors
- 👤 Panayotis G. Katsoyannis
- 👤 Gerald P. Schwartz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:27
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/62; A; A61; A61P; A61P3/00; A61P3/08; A61P3/10; A61K; A61K38/00
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
8 words
A superactive insulin analogue of the formula ##STR4##
Claim 2
Dependent Claim
8 words
A superactive insulin analogue of the formula ##STR4##
Claim 3
Dependent Claim
37 words
A pharmaceutical composition for the treatment of diabetes in a patient in need of such treatment comprising a therapeutically effective amount of a superactive human insulin analogue of the formula ##STR5## together with a pharmaceutically acceptable carrier.
Claim 4
Dependent Claim
37 words
A pharmaceutical composition for the treatment of diabetes in a patient in need of such treatment comprising a therapeutically effective amount of a superactive human insulin analogue of the formula ##STR5## together with a pharmaceutically acceptable carrier.
Claim 5
Independent Claim
37 words
A method of treating diabetes in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of a superactive insulin analogue of the formula ##STR6## together with a pharmaceutically acceptable carrier.
Claim 6
Independent Claim
37 words
A method of treating diabetes in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of a superactive insulin analogue of the formula ##STR6## together with a pharmaceutically acceptable carrier.
Claim 7
Dependent Claim
14 words
Method according to claim 3 in which the superactive insulin analogue is administered intramuscularly.
Claim 8
Dependent Claim
14 words
Method according to claim 4 in which the superactive insulin analogue is administered subcutaneously.
Claim 9
Dependent Claim
14 words
Method according to claim 5 in which the superactive insulin analogue is administered intravenously.
Claim 10
Dependent Claim
17 words
Method according to claim 6 in which the superactive insulin analogue is administered by an implantable pump.
References Cited (Backward Citations)
US3420810A
Cited
US3883496A
Cited
US3883500A
Cited
DD153829A1
Cited
US4421685A
Cited
US4430266A
Cited
US4652548A
Cited
US4652547A
Cited
US4459226A
Cited
US4526938A
Cited
US4569791A
Cited
US4581165A
Cited
US4569792A
Cited
EP0214826A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-02-11 | 1994-08-13 | 1995-02-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-02-11 | 1998-08-13 | 1999-02-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-02-11 | 2002-08-13 | 2003-02-12 | $7700.00 | Window Closed / Lapsed |